Passage Bio Inc. Common Stock is a pharmaceutical company specializing in the development of gene therapies for the treatment of rare monogenic central nervous system (CNS) diseases. With a focus on transforming patients’ lives, their innovative approach aims to provide long-term solutions for conditions with limited treatment options.
